Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOMERICA, INC.

(BMRA)
  Report
Real-time Estimate Cboe BZX  -  01:54 2022-11-28 pm EST
4.030 USD   -3.36%
11/14Biomerica Inc : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
11/02Biomerica InFoods« IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting
AQ
10/14Walmart to Offer Biomerica's Aware Breast Self Exam Device on its Retail Stores
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Biomerica : Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review (Form 8-K)

09/30/2021 | 05:12pm EST

, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

Biomerica, Inc. (the "Company") has determined that the calculation and expense of non-cash stock-based compensation, related to issued stock options, as reported in the consolidated financial statements of the Company, have been materially understated based on the application of accounting principles generally accepted in the United States. The Company has historically reported stock-based compensation expenses on the dates of vesting, rather than recognizing the expense ratably over the vesting period. The Company has also used an incorrect method for calculating forfeiture estimate for issued stock options. Stock-based compensation expense shown on the statement of operations is a non-cash expense which impacts accumulated deficit (losses) and additional paid-in capital on the balance sheet. However, this does not impact the Company's cash, revenues or other aspects of ongoing operations.

These non-cash stock-based compensation expense errors were identified by management during the implementation of a new accounting stock option software system. To confirm these findings, the Company's Audit Committee retained a third-party accounting advisory firm, to work with management and the Company's independent registered public accounting audit firm, PKF San Diego, LLP (PKF), to determine the degree by which the Company's historical financial statements were impacted.

This review has found no indication that these errors were the result of an override of controls or from misconduct at the Company. The Company's stock-based expense calculation methodology and the actual reported expense each year had been fully disclosed to, and reviewed by PKF, as part of their annual audits.

As a result of this review process, on September 29, 2021, the Audit Committee and management, in consultation with PKF and legal counsel, have determined that the Company's prior audited consolidated financial statements and the related audit report included in the Company's Annual Report on Form 10-K for the fiscal year ended May 31, 2021, as well as the Company's interim consolidated financial statements included in the Company's Quarterly Reports on Form 10-Q for the periods ended August 31, 2020, November 30, 2020 and February 28, 2021 should no longer be relied upon. As soon as possible, the Company intends to file an amended Annual Report on Form 10-K for the year ended May 31, 2021, to correct the impacted financial statements. The Company also intends to restate the above referenced fiscal year 2021 quarterly period consolidated financial statements when they are included in Quarterly Reports on Form 10-Q for the comparable periods in fiscal year 2022.

As such, the Company anticipates the following adjustments to its fiscal 2021 Form 10-K:

1) for fiscal year-ended 2021, an additional non-cash expense of $900,000 to $1,100,000, increasing net losses for the year from ($6,469,036) to between ($7,369,000) and ($7,569,000), and increasing accumulated deficit (losses) and paid-in capital each by $900,000 to $1,100,000; and

2)for fiscal year-ended 2020, an additional non-cash expense of $300,000 to $390,000, increasing net losses for the year from ($2,339,054) to between ($2,640,000) and ($2,730,000), and increasing accumulated deficit (losses) and paid-in capital each by $300,000 to $390,000.

The Company also anticipates that in order to adjust for incorrectly reported non-cash stock-based compensation expense in years prior to fiscal year 2020, it will make a one-time adjustment to its consolidated balance sheet for fiscal year-ended May 31, 2019, of $750,000 to $950,000. This adjustment will increase accumulated deficit (losses) from ($19,587,678) to between ($20,337,000) and ($20,537,000) and will increase additional paid-in capital from $22,830,006 to between $23,580,000 to $23,780,000 for the fiscal year ended May 31, 2019.

While it is anticipated that these corrective actions will be adequate, the Company intends to seek guidance from the Office of the Chief Accountant and Division of Corporation Finance at the U.S. Securities and Exchange Commission, to determine if other disclosures or changes in the Company's historical financial statements may be necessary to accurately report these corrections.

Forward-Looking Statements

Except for the statements of historical fact contained herein, the information presented in this Current Report on Form 8-K constitutes "forward-looking statements" as such term is used in applicable securities laws. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or "projects", or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results "will", "should", "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. Forward-looking statements include statements regarding the Company's intent to restate its prior financial statements and the estimated adjustments of the restated financials. There can be no assurance that the Company's management, audit committee or independent registered public accounting firm will not reach conclusions regarding the impact of the restatement that are different from management's preliminary estimates or identify additional issues or other considerations in connection with the restatement and the audit and review process or that these issues will not require additional adjustments to the Company's prior financial results. All of these statements are subject to risks and uncertainties which may cause actual results to differ materially from those stated here. These risks and uncertainties include, but are not limited to, the risk that additional information may arise from the oversight of the audit committee, the risk that the process of preparing and auditing the financial statements or other subsequent events would require the Company to make additional adjustments, the time and effort required to complete the restatement of the financial reports, the ramifications of the Company's potential inability to timely file required reports, the risk of identifying weaknesses in the Company's internal controls over financial reporting or the Company's ability to remediate such material weaknesses, the risk of litigation or governmental investigations or proceedings relating to such matters, and the risk of any potential adverse effects on the Company's business, results of operations, financial condition and stock price as a result of the restatement and correction process. Other risks are described more fully in the Company's filings with the Securities and Exchange Commission. Any such forward-looking statements are expressly qualified in their entirety by these cautionary statements. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this Current Report on Form 8-K are made as of the date of this Current Report on Form 8-K and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

2

Disclaimer

Biomerica Inc. published this content on 30 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 September 2021 21:11:03 UTC.


ę Publicnow 2021
All news about BIOMERICA, INC.
11/14Biomerica Inc : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
11/02Biomerica InFoods« IBS Data Presented at the 2022 American College of Gastroenterology ..
AQ
10/14Walmart to Offer Biomerica's Aware Breast Self Exam Device on its Retail Stores
MT
10/14Walmart to Expand Sales of Biomerica's Aware« Breast Self Exam; Product will now be ava..
AQ
10/14Walmart to Expand Sales of Biomerica’S Aware Breast Self Exam; Product Will Now Be..
CI
10/13Biomerica Reports 30% Surge in Net Sales in Fiscal Q1
MT
10/13Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022
AQ
10/13BIOMERICA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
10/13Biomerica, Inc. Reports Earnings Results for the First Quarter Ended August 31, 2022
CI
09/30Biomerica's Aware Breast Self Exam and EZ Detect Colon Disease Test Now Available on Am..
AQ
More news
Analyst Recommendations on BIOMERICA, INC.
More recommendations
Financials (USD)
Sales 2022 18,9 M - -
Net income 2022 -4,53 M - -
Net cash 2022 4,54 M - -
P/E ratio 2022 -9,72x
Yield 2022 -
Capitalization 56,0 M 56,0 M -
EV / Sales 2021 5,88x
EV / Sales 2022 2,14x
Nbr of Employees -
Free-Float 91,1%
Chart BIOMERICA, INC.
Duration : Period :
Biomerica, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMERICA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Managers and Directors
Zackary S. Irani Chairman & Chief Executive Officer
Steve Sloan Chief Financial Officer & Treasurer
Jane F. Emerson Independent Director
Allen C. Barbieri Executive Vice Chairman
Mark A. Sirgo Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIOMERICA, INC.7.20%56
ABBOTT LABORATORIES-24.00%186 493
MEDTRONIC PLC-23.52%105 241
BECTON, DICKINSON AND COMPANY-3.14%67 460
DEXCOM, INC.-16.57%43 261
HOYA CORPORATION-14.06%37 644